A new study has found a possible mechanism for tamoxifen resistance in breast cancer and provides evidence that another cancer drug--gefitinib (Iressa)--may be able to restore tamoxifens anticancer activity. The study appears in the June 16 issue of the Journal of the National Cancer Institute.
Although adjuvant tamoxifen can reduce the risk of death for women with invasive breast cancer by about 15% over 10 to 15 years, many women do not receive any benefit from the drug. Even among patients most likely to benefit from tamoxifen--those with tumors that express the drugs target, the estrogen receptor (ER)--only 40% to 50% actually benefit. Studies have shown that patients with ER-positive tumors that express high levels of HER2/neu and the ER coactivator AIB1 often develop tamoxifen resistance, but the mechanism of the resistance has not been identified.
To find this mechanism, Rachel Schiff, Ph.D. and C. Kent Osborne, M.D., of the Baylor College of Medicine in Houston, and colleagues studied molecular interactions in breast cancer cells that expressed high levels of both HER2 and AIB1. They found that, in these cells, tamoxifen acted like an estrogen agonist and stimulated tumor growth. However, when the breast cancer cells were treated with the receptor tyrosine kinase inhibitor gefitinib, tamoxifen once again acted as an estrogen antagonist and tumor growth was blocked.
Sarah L. Zielinski | EurekAlert!
New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia
New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular
16.08.2017 | Event News
04.08.2017 | Event News
26.07.2017 | Event News
18.08.2017 | Life Sciences
18.08.2017 | Physics and Astronomy
18.08.2017 | Materials Sciences